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Abstract
Background: Members of the ErbB family of growth factor receptors are intricately linked with epithelial cell
biology, development and tumourigenesis; however, the mechanisms involved in their downstream signalling are
poorly understood. Indeed, it is unclear how signal specificity is achieved and the relative contribution each
receptor has to specific gene expression.
Methods: Gene expression profiling of a human mammary luminal epithelial cell model of ErbB2-overexpression
was carried out using cDNA microarrays with a common RNA reference approach to examine long-term
overlapping and differential responses to EGF and heregulin beta1 treatment in the context of ErbB2
overexpression. Altered gene expression was validated using quantitative real time PCR and/or immunoblotting.
One gene of interest was targeted for further characterisation, where the effects of siRNA-mediated silencing on
IGF1-dependent signalling and cellular phenotype were examined and compared to the effects of loss of ErbB2
expression.
Results: 775 genes were differentially expressed and clustered in terms of their growth factor responsiveness. As
well as identifying uncharacterized genes as novel targets of ErbB2-dependent signalling, ErbB2 overexpression
augmented the induction of multiple genes involved in proliferation (e.g. MYC, MAP2K1, MAP2K3), autocrine
growth factor signalling (VEGF, PDGF) and adhesion/cytoskeletal regulation (ZYX, THBS1, VCL, CNN3, ITGA2, ITGA3,
NEDD9, TAGLN), linking them to the hyper-poliferative and altered adhesive phenotype of the ErbB2-
overexpressing cells. We also report ErbB2-dependent down-regulation of multiple interferon-stimulated genes that
may permit ErbB2-overexpressing cells to resist the anti-proliferative action of interferons. Finally, IGFBP3 was
unique in its pattern of regulation and we further investigated a possible role for IGFBP3 down-regulation in ErbB2-
dependent transformation through suppressed IGF1 signalling. We show that IGF1-dependent signalling and
proliferation were enhanced in ErbB2-overexpressing cells, whilst loss of ErbB2 expression by siRNA silencing
reduced IGF1 signalling. Furthermore, IGFBP3 knockdown resulted in basal ERK and Akt activation in luminal
epithelial cells and increased invasiveness and anchorage-independent colony formation in SKBR3 cells.
Conclusions: These data show IGFBP3 as a negative regulator of transformation and that its down-regulation
enhances IGF1-dependent signalling. They also show that ErbB2 can up-regulate IGF1-dependent signalling,
possibly via the regulated expression of IGFBP3.
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Background
The expression and activity of the ErbB/HER family of
receptor tyrosine kinases is frequently deregulated in
human cancers. To date, four members of this family
have been described: EGFR, ErbB2 (HER2), ErbB3
(HER3) and ErbB4 (HER4). Signalling through the ErbB
family is initiated by ligand-induced receptor homo- or
heterodimerzation leading to stimulation of the recep-
tors’ intrinsic tyrosine kinase activity and triggering of
auto- and cross-phosphorylation of tyrosine residues
creating docking sites for adaptor proteins and enzymes
that initiate signal transduction events ultimately leading
to changes in gene expression and altered cellular pheno-
type [1]. Numerous tumour, epithelial or stromal-derived
growth factors (GFs) bind with different affinities and
specificities to the different ErbB family members. These
include: EGF, TGFa and amphiregulin (AREG), which
bind specifically to EGFR; heparin-binding EGF-like
growth factor, betacellulin and epiregulin which bind to
both EGFR and ErbB4 [2]; and the neuregulins/heregu-
lins (HRGs), which are specific for ErbB3 and ErbB4 [3].
Although ErbB2 is an orphan receptor with no ligand
described to date, it is the preferred dimerzation partner
of the other ErbB family members, acting as a potentiator
of signalling and highlighting the importance of heterodi-
merzation within the ErbB family [3-6].
EGF and HRG can activate many intracellular signal-
ling cascades and appear to exert distinct biological
functions that depend on the nature of the receptor
complexes induced. Although there is major overlap in
the signalling pathways activated by ErbB receptors, spe-
cific family members can preferentially modulate distinct
pathways. For instance, while all ErbB receptors activate
the MAPK pathway via Shc and/or Grb2, ErbB3 is the
most potent activator of PI3K signalling due to its mul-
tiple binding sites for the p85 regulatory subunit of
PI3K [7,8]. In contrast, Eps15 and Cbl are both EGFR-
specific substrates involved in receptor down-regulation
[9,10]. The relative expression of each ErbB receptor
influences the cellular response to their ligands. For
example, cells expressing high levels of ErbB2 show a
greater response to HRG and ErbB3 shows higher affi-
nity for HRG when co-expressed with ErbB2 [11]. This
preferential cooperativity extends to oncogenic transfor-
mation, with ErbB2-ErbB3 heterodimers reported as the
most potent signalling activators [12,13]. Importantly,
the aberrant expression and/or activation of ErbB family
members have been reported in a number of different
tumour types. In particular, there is an extensive litera-
ture on the role of ErbB receptors in breast cancer.
ErbB2 is overexpressed in 25-30% of all breast cancers
due to gene amplification, and is correlated with disease
progression, advanced tumour stage, decreased survival,
poor response to therapy and metastasis [14,15]. Such
poor prognosis is a likely reflection of the biological
effects of ErbB2 overexpression, including increased
cellular proliferation, anti-apoptosis, cell invasiveness
and promotion of angiogenesis. The ErbB receptors
have consequently become targets for specific anti-can-
cer therapies [16-20]. Indeed, one of these therapies,
herceptin (trastuzumab), a monoclonal antibody against
the extracellular domain of ErbB2, has shown significant
clinical benefit for patients with ErbB2-positive breast
cancers. Indeed, the combined results of several clinical
trials have shown that the addition of 1 year of trastuzu-
mab to adjuvant chemotherapy significantly improves
disease-free survival by 33%-52% [21]. Despite this, less
than 35% of patients respond to trastuzumab as a single
agent and those who initially respond well generally
acquire resistance within a year (reviewed in [22]).
These data suggest that ErbB2 overexpression alone is
not a reliable predictor of therapeutic outcome and that
additional factors are involved. Thus, the identification
and characterization of genes associated with ErbB2
overexpression would be beneficial, in order to better
define the molecular mechanisms involved in ErbB2-
dependent transformation and to identify novel drug
targets.
Recently, much effort has been put into tumour expres-
sion profiling in an attempt to characterize the genes
involved in malignant transformation. Microarray analysis
has been reported to successfully predict estrogen receptor
and lymph-node status of breast cancer [23,24], to distin-
guish between cancers associated with BRCA1 or BRCA2
mutations [25] and to identify subclasses of breast cancer
and predict outcome based on gene expression patterns
[23,26-29]. Although these approaches are useful for iden-
tifying diagnostic and prognostic markers, few microarray
studies have examined ligand-induced signalling events
involved in transformation. The aim of this study was to
use microarray analysis to investigate ErbB ligand-induced
transcriptional responses and diversification of signalling
events downstream of ErbB receptors in a human mam-
mary luminal epithelial cell (HMLEC) model. This model
comprises an SV40 large T antigen-immortalized HMLEC
parental cell line derived from flow-sorted cells from
reduction mammoplasty material and a derivative clone
stably overexpressing ErbB2 [30,31]. The cells require
serum for proliferation, the removal of which leads to loss
of viability. In the absence of serum, treatment with the
ErbB-specific ligands HRGb1 or EGF can support prolif-
eration and survival, with the ErbB2-overexpressing
cells displaying increased rates of proliferation, anchorage-
independent growth and enhanced mitogenic signalling
compared to the parental line [31,32]. In the present
study, cells were serum-starved and treated with EGF or
Worthington et al. BMC Cancer 2010, 10:490
http://www.biomedcentral.com/1471-2407/10/490
Page 2 of 22
HRGb1 over a timecourse to establish long-term HRG-
and EGF-specific transcriptional responses to examine
diversification of signalling through EGFR and ErbB3
receptors and to assess how ErbB2 overexpression alters
these responses.
Methods
Cell culture, growth factor stimulation and RNA isolation
The parental HMLEC line HB4a and an ErbB2-overex-
pressing derivative C3.6 have been previously described
[31,32]. Cells were cultured in RPMI-1640 media supple-
mented with 10% fetal calf serum (FCS), 2 mM glutamine,
100 IU/ml penicillin, 100 μg/ml streptomycin, 5 μg/ml
hydrocortisone and 5 μg/ml insulin (both Sigma) at 37°C
in a 10% CO2 humidified incubator. Before stimulation,
HB4a and C3.6 cells were starved of GFs for 48 h in
RPMI-1640 media with 0.1% FCS, 100 IU/ml penicillin,
100 μg/ml streptomycin and 5 μg/ml hydrocortisone. Cells
were then treated with 1 nM EGF or 1 nM HRGb1 (HRG
hereafter) (both R&D Systems) for 4 h, 18 h and 24 h
prior to RNA isolation. Two plates were prepared for con-
trol (serum-starved) cells and for each time point. Total
RNA was isolated using TRIZOL™ reagent (Invitrogen Life
Technologies) according to the manufacturer’s protocol.
Each plate generated two samples of total RNA for reci-
procal labelling, resulting in a total of four replicates for
microarray experiments. Serum starved cells were also
treated with 25 ng/mL IGF1 for the indicated times.
SKBR3 cells were maintained in tissue culture flasks con-
taining DMEM/F-12 medium supplemented with 10%
(v/v) FCS, 100 μg/mL streptomycin and 100 IU/mL peni-
cillin (Gibco-Invitrogen Corp) in a humidified incubator at
37˚C with 5% CO2.
Microarray experimental design
Hver 1.3.1 arrays used in this study were obtained from
the Wellcome Trust Sanger Institute. Each microarray
contains a redundant set of 9932 PCR-derived, sequence
verified cDNA clones representing around 6,000 genes.
25 μg of total RNA was used to produce labeled cDNA by
anchored oligo(dT)-primed reverse transcription with
Superscript II Reverse Transcriptase (Invitrogen Life
Technologies) in the presence of Cy3- or Cy5-dUTP
(Amersham Pharmacia). Unincorporated Cy dye was
removed using Autosequ-50 Columns (Amersham Phar-
macia) and repetitive DNA sequences were blocked by co-
precipitation of labeled cDNA with 8 μg Cot1 (Boehringer
Mannheim) and 8 μg poly(dA) DNA (Sigma). The labeled
cDNA pellet was re-suspended in hybridization buffer (4 ×
SSC, 5× Denhardt’s solution, 50 mM Tris-HCl pH 7.6,
0.1% sarkosyl, 49% formamide) and hybridized onto arrays
at 47°C overnight. Slides were washed twice in 2 × SSC,
four times in 0.1 × SSC plus 0.1% SDS, twice in 0.1 × SSC
and then dried by centrifugation before scanning.
All samples were co-hybridized to a common standard
reference comprised of total RNA pooled from cell line
BT474 and two grade III invasive ductal breast carcinomas
(gift of Dr Alan Mackay, ICR, London), allowing cross-
comparison of multiple experimental conditions. A “-
dye-flip” approach was used to minimize dye-specific bias,
where two biological replicates were labeled with Cy3 and
hybridized with Cy5-labelled reference and vice versa (four
replicates). For the 14 experimental conditions (2 cell
lines, 2 GFs and 3 time points plus untreated), a total of
56 hybridizations were thus performed.
Data normalization, filtering and analysis
Slides were scanned using ScanArray 4000XL and spots
quantified using QuantArray v3.0 (both Packard Bio-
Chip Technology). Cy-dye emission signals were scaled
in QuantArray using the median intensity of each chan-
nel, and any visible hybridization artifacts were flagged
and recorded as absent during data filtering and analy-
sis. Data was background subtracted and exported to
GeneSpring v6.1 (Silicon Genetics) for normalization.
The fluorescence intensity ratio between each sample
and the co-hybridized reference (sample/ref) was calcu-
lated and represents the expression level for a given
probe on each individual replicate. The dataset was
then normalized using the intensity-dependent LOW-
ESS regression technique [33]. Normalized raw data and
experimental details were processed to conform with
Minimum Information About a Microarray Experiment
(MIAME) guidelines and are deposited in the Array
Express (http://www.ebi.ac.uk/arrayexpress) repository
(accession number E-TABM-106). Genes were then fil-
tered using the excel add-in SAM (Significant Analysis
of Microarray) [34] to identify genes showing significant
changes in expression by assigning a score on the basis
of change in gene expression relative to the standard
deviation of repeated measurements. A false discovery
rate threshold of 3% was used as the cut-off to report
differentially regulated genes. Averaged values for each
of the 14 experimental conditions were then compared
to identify genes that were up- or down-regulated gen-
erating a list of 775 genes that changed significantly
between two or more experimental conditions. TIGR
MeV software v2.2 (The Institute for Genomic
Research) was used for clustering analysis of the 775
genes using two sets of average ratios: i) the HB4a/C3.6
ratio was taken at each time point for ErbB2-dependent
changes in gene expression, and ii) the T*/T0 ratio was
taken in each cell line for GF-dependent changes in
gene expression. Values were log2 transformed, loaded
into TIGR MeV for average-linkage hierarchical cluster-
ing using Euclidian Distance and for k-means clustering
using 4 (k) groups. Genes in each group were then sub-
jected to hierarchical clustering.
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Semi-quantitative Real Time-PCR
Samples were generated by reverse transcription of 2.5 μg
of total RNA using Superscript II Reverse Transcriptase
(Invitrogen Life Technologies) and random hexamer pri-
mers (Applied Biosystems). cDNAs were then treated with
RNase H (Invitrogen Life Technologies) to eliminate RNA
contamination. Real Time-PCR (qRT-PCR) was performed
using the Assay-on-Demand system (Applied Biosystems)
according to the manufacturer’s protocol. Assay IDs were:
Hs99999905_m1 (GAPDH); Hs99999901_s1 (18S);
Hs00155832_m1 (AREG); Hs00426287_m1 (IGFBP3);
Hs00192713_m1 (G1P2); Hs00175188_m1 (CTSC);
Hs00196051_m1 (ISGF3G); Hs00242943_m1 (OAS1);
Hs00195584_m1 (S100P); Hs00602835_s1 (SFN);
Hs00173626_m1 (VEGF); Hs00185574_m1 (VIL2);
Hs00185584_m1(VIM); Hs00170299_m1 (ZYX). Briefly,
primer and probe mix was added to PCR Master Mix with
1 μL of cDNA per 50 μL reaction. Sample fluorescence
emission was recorded for each cycle on an ABI7700
Sequence Detection System. Cycling conditions were as
follows: initial enzyme activation step at 95°C for 10 min
and then 39 repeating cycles of 95°C for 10 sec and 60°C
for 1 min. Serial dilution experiments of each primer
against the endogenous control were prepared to test for
amplification efficiency. For primers whose amplification
efficiencies were similar to that of the endogenous control
(slope of the graph ΔCt vs. log dilutions ≤0.1) the ΔCt
method was used, where the equation 2-ΔΔCt determines
the amount of a target relative to a calibrator sample. If
amplification efficiencies were not similar, the standard
curve method was used for relative quantitation of target
gene expression. Further information on both of these
methods can be found on User Bulletin3 on the ABI
website.
Immunoblotting
Freshly treated cells were lysed in NP40 lysis buffer
(50 mM HEPES pH 7.4, 150 mM NaCl, 1% NP40, 1
mM EDTA) with protease and phosphatase inhibitors:
pepstatin A (1 μg/mL), leupeptin (1 μg/mL), AEBSF
(100 μg/mL), aprotinin (17 μg/mL), sodium orthovana-
date (2 mM), okadaic acid (1 μM), fenvalerate (5 μM)
and bpV (5 μM). Protein concentration was determined
using a Bradford assay and equal amounts of protein
used for SDS-PAGE and immunoblotting with commer-
cially-available antibodies (Additional file 1). Antibodies
were detected with appropriate HRP-conjugated second-
ary antibodies and detected by enhanced chemilumines-
cence (Perkin Elmer). All membranes were reprobed for
beta-actin and densitometry performed on all bands
using a GS-800 Calibrated Densitometer and Quanti-
tyOne software (both BioRad) with local background
subtraction. Intensities for each band were then normal-
ized to the actin band in that lane. Normalized values
were averaged from 3-5 independent blots and plotted
using the standard deviation as the error.
Small interfering RNA (siRNA) reverse transfection
HB4a, C3.6, or SKBR3 cells were withdrawn from anti-
biotics for a minimum of 2 hrs and subsequently trans-
fected with siRNA pools targeting ErbB2, IGFBP3 or
non-targeting scrambled control siRNA (Dharmacon
RNA Technologies); the ON-TARGET plus non-target-
ing control siRNA pool was used in invasion, prolifera-
tion and stimulation assays, whilst the #2 ON-TARGET
plus non-targeting control siRNA was used in ancho-
rage-independence growth assays. Reverse transfection
was performed in 6-well plates according to the manu-
facturer’s instructions using Lipofectamine™ RNAi Max
(Invitrogen) and diluting the siRNA with Opti-Mem®
reduced serum medium (Invitrogen). A final concentra-
tion of 50 nM of siRNA was typically used to transfect
2.5 × 105 cells per well (or 1.5 × 105 for siIGFBP3
knockdown in SKBR3) which were then maintained in
their normal growth medium. Cells were typically har-
vested 96 hrs post-transfection in 200 μL of NP40 lysis
buffer and expression knockdown confirmed by western
blotting as described.
Invasion assays
Transfected SKBR3 cells were subjected to a matrigel-
based invasion assay utilizing a 24-well BD Biocoat™
Tumour Invasion Assay System (BD Biosciences)
according to the manufacturer’s instructions. At
96 hours post-transfection, cells were harvested, counted
and plated at 1 × 105 cells/chamber in DMEM/F-12
medium supplemented with 0.1% (v/v) FCS, 100 μg/mL
streptomycin and 100 IU/mL penicillin. The lower
chamber contained a chemo-attractant of DMEM/F-12
medium supplemented with 10% (v/v) FCS. Invaded
cells on the underside of the membrane were fixed and
stained after 72 hours in a 99% methanol, 1% crystal
violet solution and counted under a bright field micro-
scope with the Image J software. Experiments were per-
formed in triplicate for each siRNA and cells in 5 fields
per membrane were counted.
Proliferation assays
Transfected cells were harvested after 96 hrs, counted
and plated at 3 × 103 (SKBR3) and 5 × 103 cells/well
(HMLEC) into 96-well plates in DMEM/F-12 medium
supplemented with 10% (v/v) FCS, 100 μg/mL strepto-
mycin and 100 IU/mL penicillin with 5 replicates per
condition. The number of viable cells was ascertained
utilizing a MTT (3-(4, 5-dimehylthiazol-2-yl)-2-5-
dyphennyltetrazolium bromide) assay after 48 hrs. For
this, cells were incubated with 50 μL/well of 1 mg/mL
MTT which is converted to purple formazan crystals by
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viable cells. After 5 hr crystals were solubilised in
100 μL of DMSO, shaken at room temperature for
10 min and the absorbance measured at 540 nm using a
microtitre plate spectrophotometer.
Anchorage-independence growth assays
Transfected SKBR3 cells were harvested after 96 hrs,
counted and re-suspended in DMEM/F-12 medium sup-
plemented with 10% (v/v) FCS, 100 μg/mL streptomy-
cin, 100 IU/mL penicillin and 10% (v/v) of a 10 mg/mL
bacto-peptone solution which contained 3.3% (v/v)
noble agar (both Sigma). Cells were plated at 2 × 104
cells/well into 6-well plates containing DMEM/F-12
medium supplemented with 10% (v/v) FCS, 100 μg/mL
streptomycin, 100 IU/mL penicillin and 10% (v/v) of a
10 mg/mL bacto-peptone solution with 6% (v/v) noble
agar. Colonies were fixed and stained after 14 days with
1 mg/mL p-iodotertazolium violet (Sigma) prepared in
absolute methanol and counted using the Image J soft-
ware. Experiments were performed in triplicate and 5
fields were counted per plate.
Results
ErbB2 and growth factor cDNA microarray analysis
Our aim was to identify time-dependent and growth fac-
tor-specific changes in gene expression associated with
long-term EGF and HRGb1 (hereafter HRG) stimulation
of a model HMLEC system. The concentrations of
growth factor used (1 nM) were selected based on mini-
mum concentrations required for maximal activation of
the ERK1/2 and Akt pathways as measured by western
blotting with phospho-specific antibodies (data not
shown). We also wanted to assess how such gene
expression changes are affected by ErbB2 overexpression
in order to understand how ErbB2 contributes to signal-
ling events associated with breast epithelial cell transfor-
mation. Microarray experiments were thus carried out
using a previously described ErbB2-overexpressing
HMLEC system [31,32]. Serum-starved HB4a parental
cells and ErbB2-overexpressing C3.6 cells were stimu-
lated with EGF or HRG for 4 h, 18 h and 24 h or left
unstimulated (0 h) prior to microarray analysis of
mRNA levels of 9,932 probes, representing ~6,000
genes. These timepoints were chosen to assess the med-
ium-term effects on gene expression that occur within
the doubling time of the cells.
Four replicates of each sample were co-hybridized to
chips with a common RNA reference allowing direct com-
parison of gene expression across all experimental condi-
tions: time, GF and cell line. The excel add-in software
SAM (Significance Analysis of Microarray) [34] was used
to perform pair-wise comparisons of all conditions, identi-
fying 1,995 significant changes, representing 775 genes
whose expressions were either responsive to EGF and/or
HRG, genes differentially regulated by ErbB2 overexpres-
sion, or both. Of these, 145 genes occurred more than
once where probes on the arrays corresponded to different
sequences of the same gene. In general, these duplicates
and triplicates displayed similar patterns of expression,
increasing confidence in the observed changes. Full gene
lists grouped by responsiveness are available in Additional
file 2. Fig 1A and 1B show the number of genes and their
overlapping responses. There were a greater number of
genes up- or down-regulated by HRG in the C3.6
cells than EGF, whilst EGF was generally more potent at
inducing expression in the HB4a parental cells. Time-
dependent changes in the response to each GF were also
apparent between cell lines, indicating that ErbB2 overex-
pression alters the kinetics of downstream signalling
events. Functional classification of the 775 genes revealed a
wide range of gene families, with kinases, CD antigens and
receptors featuring prominently (Fig. 1C). There were sur-
prisingly few known EGF-responsive genes, although this
may reflect the timepoints employed and/or insufficient
database annotation. Fifty-two genes had no functional
annotation and represent novel genes that warrant further
study.
Ratios of normalized values were next used to show rela-
tive gene expression in two ways: (i) the EGF or HRG
ratio (T*/T0) representing gene expression at each time-
point relative to untreated control for both cell lines, and
(ii) the ErbB2 ratio (C3.6/HB4a) representing relative
gene expression in C3.6 versus HB4a cells at each time-
point. Ratios were used for unsupervised hierarchical
clustering of all 775 genes (Fig. 2). Although no striking
functional clusters were apparent, there were several
interesting features. One group of genes displayed altered
expression correlating with ErbB2, but displayed similar
levels of up- or down-regulation in response to both
growth factors (light green and pink bands, Fig. 2). A
second group of genes was down-regulated by ErbB2, but
potently up-regulated by EGF treatment (light blue
band). A third large group of genes displayed transient
induction (up at 4 h only) in all treatments, but less so
with HRG in the HB4a cells (red band). A fourth group
of genes were down-regulated in response to both GFs
(dark green band). Finally, two features clustered away
from the other 773 genes (top of cluster in Fig. 2) and
represented IGFBP3, a putative regulator of insulin-like
growth factor (IGF)-dependent and independent prolif-
eration, differentiation and survival. IGFBP3 expression
was strongly suppressed by ErbB2 overexpression and
down-regulated by both GFs (Fig. 3A &3B).
Growth factor-induced genes augmented by ErbB2
overexpression
Genes transiently induced by both GFs and whose
expressions were induced more strongly in the
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ErbB2-overexpressing cells are of particular interest in
ErbB2-dependent cell transformation. These genes
included transcription factors MYC (Fig. 3C),
ZFP36L1, ZFP36L2, FOSL1 and ATF4/CREB2, growth
factors VEGF and PDGFB and signalling kinases LYN,
MAP2K1/MEK1 and MAP2K3/MEK3 (Fig. 3D). Also
in this group, were the MYC-induced glycoprotein
EMP1, which showed a similar pattern of expression to
MYC (Fig. 3E), and BCAR3 (Fig. 3F), a novel SH2 and
GEF domain-containing gene. A number of genes asso-
ciated with cytoskeletal organization and adhesion
were also induced more robustly in the ErbB2 overex-
pressing cells, particularly in response to HRG. These
genes included zyxin (ZYX) (Fig. 3G), transgelin
Figure 1 Numbers and functions of differentially expressed genes. A. Venn diagram showing the distribution of the 775 genes found to be
significantly differentially expressed and their co-regulation by EGF, HRG and ErbB2. B. Distribution of up- or down-regulated genes by cell line
and growth factor (left) and in C3.6 vs. HB4a over time (right). C. Distribution of functional classes of differentially regulated genes based on GO
terms for molecular function.
Worthington et al. BMC Cancer 2010, 10:490
http://www.biomedcentral.com/1471-2407/10/490
Page 6 of 22
Figure 2 Hierarchical clustering of 775 differentially expressed genes. Ratios of normalized values were used to show relative gene
expression in two ways: (i) the EGF or HRG ratio (T*/T0) representing relative gene expression at each timepoint in relation to the untreated
control, measuring the response to each ligand in HB4a and C3.6 cells separately, and (ii) the ErbB2 ratio (C3.6/HB4a) representing relative gene
expression in C3.6 vs. HB4a at each time point, identifying genes whose expression are affected by ErbB2. Ratios were log2 transformed and
loaded into TIGR MeV software v2.2 (Institute for Genomic Research) and unsupervised, average-linkage hierarchical clustering performed.
Clusters indicated by light green and pink bands (on right) show genes whose expressions were altered by ErbB2 overexpression, but were
similarly up- or down-regulated by EGF and HRG; the light blue cluster shows genes down-regulated by ErbB2, but up-regulated by EGF; the
dark green cluster shows genes that were down-regulated by both growth factors and the red cluster shows genes that were transiently-
induced in all treatments except in HRG-treated HB4a cells.
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Figure 3 Examples of growth factor and ErbB2-dependent differential gene expression. Plots of relative gene expression (averaged (n = 4)
normalised fluorescence intensity) versus time are shown for 20 genes. Data for both microarray clones are shown for IGFBP3. Genes showing a
change in expression following growth factor treatment and significantly different between the cell lines were: IGFBP3_1 (1.18-fold increase in
HB4a versus 1.3-fold decrease in C3.6 with EGF (0 to 4 hr); MYC (1.05-fold decrease in HB4a versus 3.09-fold increase in C3.6 with HRG (0 to 4 hr);
MAP2K3 (1.39-fold increase in HB4a versus 2.49-fold increase in C3.6 with HRG (0 to 4 hr); BCAR3 (1.52-fold increase in HB4a versus 3.18-fold
increase in C3.6 with HRG (0 to 4 hr); ZYX (1.05-fold decrease in HB4a versus 3.17-fold increase in C3.6 with HRG (0 to 4 hr); PLAT2 (1.18-fold
increase in HB4a versus 2.13-fold increase in C3.6 with EGF (0 to 4 hr) and 1.01-fold increase in HB4a versus 2.76-fold increase in C3.6 with HRG
(0 to 4 hr); TNFAIP3 (4.98-fold increase in HB4a versus 7.74-fold increase in C3.6 with EGF (0 to 4 hr); GADD45A (1.26-fold increase in HB4a versus
2.82-fold increase in C3.6 with HRG (0 to 4 hr); S100A2 (2.88-fold increase in HB4a versus 1.02-fold increase in C3.6 with EGF (0 to 4 hr); ERBB2
(3.13-fold decrease in HB4a versus 1.48-fold increase in C3.6 with HRG (0 to 4 hr); ZNF236 (4.85-fold increase in HB4a versus 2.83-fold increase in
C3.6 with HRG (0 to 4 hr).
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(TAGLN), thrombospondin 1 (THBS1), vinculin (VCL),
calponin 3 (CNN3), villin 2/ezrin (VIL2), myosin 1E
(MYO1E), stathmin 3 (STMN3), Crk-associated sub-
strate-related protein (NEDD9/CASL), ladinin 1
(LAD1) and integrin a2 and a3 (ITGA2 and ITGA3).
Members of the plasminogen activator system; tissue-
type plasminogen activator (PLAT) (Fig 3H), uroki-
nase-type plasminogen activator receptor (PLAUR),
plasminogen activator inhibitor 1 (PAI1/SERPINE1)
and the plasminogen and PLAT co-receptor annexin
A2 (ANXA2), were also present in this group. The
anti-apoptotic genes IER3 and TNFAIP3 (Fig. 3I &3J)
were also more highly induced in the ErbB2-overex-
pressing cells, as were the poorly characterized genes
S100P, CSRP1, HPCAL1 and SMAP, identifying them
as potential effectors of ErbB signalling. Finally, and
perhaps surprisingly, the genotoxic stress-induced
growth arrest gene GADD45A (Fig. 3K) and the
MAPK phosphatases DUSP1/MKP1 and DUSP5 were
both induced by growth factor treatment.
Growth factor-induced gene expression changes
In order to analyze EGF and HRG-specific changes in
gene expression regardless of ErbB2 level, three gene
lists were generated according to the Venn diagram in
Fig. 1A: (i) EGF-responsive (199 genes); (ii) HRG-
responsive (269 genes); and (iii) genes responsive to
both (135 genes). Genes in each list were grouped by
k-means clustering into 4 clusters displaying similar pat-
terns of expression. Fig 4A shows the average expression
patterns for genes regulated by both GFs and reveals
that a considerable number were less potently induced
(or not induced) by HRG in the HB4a cells (Fig. 4A;
clusters 2 & 3). Of the 13 genes in cluster 2 (Figs. 4A &
Additional file 3), six were clones of the metallothionein
(MT) family of cysteine-rich, heavy metal-binding pro-
teins and were potently induced by EGF (Fig. 3M). This
cluster also included cytoskeletal components keratin 6
(KRT6D/B), transgelin (TAGLN) and coactosin-like 1
(COTL1) and a novel polyadenylation protein variant
tauCstF-64 (CSTF2T) (Fig. 3N). Cluster 3 genes (Fig.
4B) included SFN, a negative regulator of G2/M pro-
gression and the adhesion-related genes villin 2/ezrin
(VIL2), syndecan 4 (SDC4), integrin-a3 (ITGA3), integ-
rin-b1 (ITGB1) laminin-a3 (LAMA3), paxillin (PXN)
and vinculin (VCL). Clusters 1 and 4 showed a more
similar pattern of regulation in the two cell lines and
their regulation is therefore less likely to be dependent
upon ErbB2 signalling. Cluster 1 genes were down-regu-
lated in response to GF treatment and included genes
involved in the response to oxidative stress (PRDX5,
GSTP1, MGST3, TXNIP and ALDH1A3). Notably, a
gene of unknown function (MGC10471/CCDC130) was
potently repressed by both GFs in HB4a cells, and was
constitutively down-regulated in C3.6 cells, similar to
IGFBP3 (Fig. 3L). Such novel genes are of particular
interest since they may be components of as yet unchar-
acterized GF-dependent pathways. wfdc2 Cluster 4
genes were moderately up-regulated by EGF and HRG,
and included genes with reported roles in proliferation
and tumour suppression, such as MYBL2, FOXM1,
NME1 (Fig. 3O) and PHB (Fig. 3P).
Genes induced specifically by EGF included C14orf31,
CDH3, CAV1, ACTB, CTNNAL1, PTPN1, S100A11,
TIMP1, TMSB10 and TXN, linking them to signalling
through EGFR-containing dimers. A group of EGF-specific
genes were induced almost exclusively in HB4a cells and
included the EGFR ligand AREG (Fig. 5), the cysteine pro-
tease cathepsin C (CTSC) (Fig. 5), the Ca2+-binding pro-
tein S100A2 (Fig. 3Q) and hypoxia inducible factor 2A
(HIF2A), a transcription factor involved in the induction
of oxygen-regulated genes such as VEGF (see above).
There were no genes exclusively down-regulated by EGF,
although IGFBP3 and the transmembrane glycoprotein
MUC1 showed a stronger response to EGF than HRG.
There were significantly more genes responsive to HRG,
and although the inductions were generally weaker, their
expressions were often sustained. ERBB2 and ERBB3
(Fig. 3R &3S) were among the genes down-regulated by
HRG, suggesting a feedback mechanism through regulated
transcription. Noticeably, ERBB2 and ERBB3 gene expres-
sion was higher in the C3.6 cells, in accordance with pre-
viously established protein levels [32]. Genes potently
induced by HRG compared to EGF included metabolic
enzymes, transcription factors (MADH4 and STAT1), the
cell cycle inhibitor CDKN1A/p21CIP, the protease inhibi-
tor SLPI, fibronectin 1 (FN1), keratin 15 (KRT15) and the
poorly characterized NUP214 and zinc finger-containing
gene (ZNF236) (Fig. 3T). Figures of K-means clusters of
genes regulated by either EGF or HRG can be found in
Additional files 4 and 5.
ErbB2-dependent gene expression
A group of genes displayed differential expression
between the cell lines, but were either unresponsive to
GF treatment or responded similarly in the two cell
lines (Table 1). These included several metabolic
enzymes that were more highly expressed in the C3.6
cells, and eight known interferon-stimulated genes
(ISGs) that displayed reduced expression. The ISGs
included the ubiquitin-like modifier G1P2/ISG15, which
was the most suppressed gene in the dataset (Fig. 3U),
and ISGF3G/p48/IRF9, the third component of a STA-
T1and STAT2-containing transcription factor complex
that controls interferon (IFN)-mediated gene expression.
Finally, several genes of poorly-defined or unknown
function (AGR2, PSCA, PKM2, NME1, CPNE3, LCP1,
S100P, SERF2 and LOC402057) were constitutively
Worthington et al. BMC Cancer 2010, 10:490
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Figure 4 K-means clustering and hierarchical clustering of EGF and HRG-responsive genes. A. For k-means clustering in TIGR MeV
software v2.2 (Institute for Genomic Research), growth factor-responsive genes from SAM were grouped separately and sub-divided into a user-
defined number (k = 4) of groups. Plots show the four groups as average expression patterns for genes regulated by both growth factors. B.
Group 3 genes which were transiently induced by both growth factors except by HRG in HB4a cells were subjected to hierarchical clustering as
above.
Worthington et al. BMC Cancer 2010, 10:490
http://www.biomedcentral.com/1471-2407/10/490
Page 10 of 22
up-regulated in the C3.6 cells (Table 1) and may repre-
sent novel markers of ErbB2-dependent transformation.
Validation of gene expression changes
A set of genes of interest from the microarray analysis
were chosen for validation using semi-quantitative real-
time PCR and/or immunoblotting. In general, there was
good agreement between the microarray and RT-PCR
datasets for genes examined, although fold-changes were
generally higher and data more reproducible for the RT-
PCR analyses (Fig. 5). Thus, EGF and/or HRG treatment
induced AREG, VEGF, SFN, VIL2, ZYX and CTSC
expression, with a more potent induction of VIL2 and
ZYX in C3.6 cells, in agreement with the microarray
data. Also in agreement, IGFBP3 and three ISGs
(ISGF3G, G1P2 and OAS1) were all expressed at lower
levels in C3.6 cells with IGFBP3 potently down-regu-
lated by both GFs in the HB4a cells, whilst S100P was
overexpressed in the C3.6 cells. One exception was
vimentin (VIM), where RT-PCR showed increased
expression in C3.6 cells with potent induction by EGF
and HRG, rather than the down-regulation suggested
Figure 5 Comparison of microarray and real time RT-PCR data. Real time RT-PCR was performed on 12 target genes using Applied
Biosystems’ Assay-on-Demand and relative gene expression calculated using the ΔCt or standard curve method (see Methods for details).
Worthington et al. BMC Cancer 2010, 10:490
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Table 1 Genes displaying differential expression between HB4a and C3.6 cell lines
Symbol Ensembl Number and Description GO Biological Process Fold Change
(at T0)
*ALDH1A3 ENSG00000184254:ALDEHYDE DEHYDROGENASE 6 GO:0006629:lipid metabolism 5.45
KRT15 ENSG00000171346:KERATIN, TYPE I CYTOSKELETAL 15 GO:0008544:epidermal differentiation 4.66
*AGR2 ENSG00000106541:ANTERIOR GRADIENT 2 Unknown 4.00
NCKAP1 ENSG00000061676:NCK-ASSOCIATED PROTEIN 1 (NAP 1) GO:0006915:apoptosis 3.87
COX6C ENSG00000164919:CYTOCHROME C OXIDASE POLYPEPTIDE VIC GO:0006091:energy pathways 3.37
PSCA ENSG00000167653:PROSTATE STEM CELL ANTIGEN PRECURSOR Unknown 2.94
*KRT13 ENSG00000171401:KERATIN, TYPE I CYTOSKELETAL 13 GO:0008544:epidermal differentiation 2.69
YWHAZ ENSG00000164924:14-3-3 PROTEIN ZETA/DELTA GO:0007165:signal transduction 2.47
*S100P ENSG00000163993:S-100P PROTEIN Unknown 2.45
*PKM2 ENSG00000067225:PYRUVATE KINASE, MUSCLE GO:0006096:glycolysis 2.41
TRAM1 ENSG00000067167:TRAM PROTEIN GO:0006605:protein targeting 2.38
ATP5L ENSG00000167283:ATP SYNTHASE G CHAIN, MITOCHONDRIAL GO:0015992:proton transport; GO:0006754:ATP
biosynthesis
2.26
SLC7A7 ENSG00000155465:Y+L AMINO ACID TRANSPORTER 1 GO:0006832:small molecule transport 2.25
SSBP1 ENSG00000106028:SINGLE-STRANDED DNA-BINDING PROTEIN GO:0006260:DNA replication 2.25
SERF2 ENSG00000140264:SMALL EDRK-RICH FACTOR 2 Unknown 2.21
NEDD9 ENSG00000111859:ENHANCER OF FILAMENTATION 1 (HEF1) GO:0007155:cell adhesion; GO:0000074:regulation of
cell cycle
2.18
SCAMP2 ENSG00000140497:SECRETORY CARRIER-ASSOCIATED MEMBRANE
PROTEIN 2
GO:0006886:intracellular protein transport 2.12
EMP1 ENSG00000134531:EPITHELIAL MEMBRANE PROTEIN-1 GO:0007048:oncogenesis;GO:0008283:cell proliferation 2.10
*LCP1 ENSG00000136167:L-PLASTIN Unknown 2.09
MGST1 ENSG00000008394:MICROSOMAL GLUTATHIONE S-TRANSFERASE
1




DDX5 ENSG00000108654:PROBABLE RNA-DEPENDENT HELICASE P68 GO:0016049:cell growth 2.00
SRP14 ENSG00000140319:SIGNAL RECOGNITION PARTICLE 14 KDA
PROTEIN
GO:0006605:protein targeting 1.98




ATP5G3 ENSG00000154518:ATP SYNTHASE LIPID-BINDING PROTEIN GO:0006091:energy pathways; GO:0015992:proton
transport
1.78
SRI ENSG00000075142:SORCIN (22 KDA PROTEIN) GO:0007517:muscle development 1.77
RPL17 ENSG00000141618:60S RIBOSOMAL PROTEIN L17 GO:0006412:protein biosynthesis 1.71
*ERBB2 ENSG00000141736:V-ERBB2 ERYTHROBLASTIC LEUKEMIA VIRAL
ONCOGENE HOMOLOG 2
GO:0007169:transmembrane receptor protein tyrosine
kinase signaling
1.67
*AKR1B1 ENSG00000085662:ALDOSE REDUCTASE GO:0005975:carbohydrate metabolism 1.66
ATP6V1F ENSG00000128524:VACUOLAR ATP SYNTHASE SUBUNIT F GO:0015992:proton transport; GO:0006754:ATP
biosynthesis
1.66
ATP5G1 ENSG00000159199:ATP SYNTHASE LIPID-BINDING PROTEIN GO:0015992:proton transport 1.64
UBN1 ENSG00000118900:UBINUCLEIN 1 GO:0016568:chromatin modification 1.63
*ERBB3 ENSG00000065361:V-ERBB2 ERYTHROBLASTIC LEUKEMIA VIRAL
ONCOGENE HOMOLOG 3
GO:0007169:transmembrane receptor protein tyrosine
kinase signaling
1.62
FTH1 ENSG00000167996:FERRITIN HEAVY CHAIN GO:0008283:cell proliferation; GO:0006826:iron
transport
1.62
ST14 ENSG00000149418:SUPPRESSOR OF TUMORIGENICITY 14 GO:0006508:proteolysis and peptidolysis 1.62
*PHB ENSG00000167085:PROHIBITIN GO:0008151:cell growth and/or maintenance 1.59
CLTC ENSG00000141367:CLATHRIN HEAVY CHAIN 1 GO:0006886:intracellular protein transport 1.51
APLP2 ENSG00000084234:AMYLOID-LIKE PROTEIN 2 PRECURSOR GO:0007186:G-protein coupled receptor protein
signaling pathway
1.48
Worthington et al. BMC Cancer 2010, 10:490
http://www.biomedcentral.com/1471-2407/10/490
Page 12 of 22
Table 1 Genes displaying differential expression between HB4a and C3.6 cell lines (Continued)
HSBP1 ENSG00000166530:HEAT SHOCK FACTOR BINDING PROTEIN 1 GO:0000122:negative regulation of transcription from
Pol II promoter
1.48
*NME1 ENSG00000239672:NON-METASTATIC CELLS 1 GO:0045786:negative regulation of cell cycle;
GO:0009142: NTP biosynthesis
1.47
*CPNE3 ENSG00000085719:COPINE III Unknown 1.46
*ISGF3G † ENSG00000213928:INTEREFERON REGULATORY FACTOR 9 GO:0006355:regulation of transcription; GO:0006955:
immune response
0.73
*USP14 † ENSG00000101557:UBIQUITIN SPECIFIC PEPTIDASE 14 GO:0006511:ubiquitin-dependent protein catabolism 0.71
SSR4 ENSG00000180879:SIGNAL SEQUENCE RECEPTOR DELTA GO:0006886:intracellular protein transport 0.69
RAB7 ENSG00000075785:RAS-RELATED PROTEIN RAB-7 GO:0007264:small GTPase mediated signal
transduction; GO:0006897:endocytosis
0.69
SHMT2 ENSG00000182199:SERINE HYDROXYMETHYLTRANSFERASE GO:0006520:amino acid metabolism 0.68
NGFRAP1 ENSG00000166681:NERVE GROWTH FACTOR RECEPTOR
ASSOCIATED PROTEIN 1
GO:0007275:development; GO:0006915:apoptosis 0.66
HAT1 ENSG00000128708:HISTONE ACETYLTRANSFERASE 1 GO:0006323:DNA packaging; GO:0006475: internal
protein amino acid acetylation
0.65
PPP1CA ENSG00000172531:SERINE/THREONINE PROTEIN PHOSPHATASE
PP1-ALPHA 1 CATALYTIC SUBUNIT
GO:0006470:protein amino acid dephosphorylation 0.65
UBL1 ENSG00000116030:UBIQUITIN-LIKE PROTEIN SMT3C PRECURSOR GO:0006281:DNA repair 0.65
NPC2 ENSG00000119655:EPIDIDYMAL SECRETORY PROTEIN E1
PRECURSOR
GO:0000004:biological_process unknown 0.65
GMPS ENSG00000163655:GMP SYNTHASE GO:0006164:purine nucleotide biosynthesis 0.62
UBE2L6 † ENSG00000156587:UBIQUITIN-CONJUGATING ENZYME E2L 6 GO:0006512:ubiquitin cycle 0.61
SF3B1 NSG00000115524:SPLICING FACTOR 3B SUBUNIT 1 GO:0006371:mRNA splicing 0.58
ANXA1 ENSG00000135046:ANNEXIN I GO:0006928:cell motility;GO:0006629:lipid metabolism 0.57
SDC1 ENSG00000115884:SYNDICAN 1 GO:0048627:myoblast development 0.56
FXR1 ENSG00000114416:FRAGILE X MENTAL RETARDATION
SYNDROME RELATED PROTEIN 1
GO:0006915:apoptosis 0.56




*GSTP1 † ENSG00000084207:GLUTATHIONE S-TRANSFERASE P GO:0007417:central nervous system development 0.51





TYMS ENSG00000176890:THYMIDYLATE SYNTHASE GO:0006139:nucleobase, nucleoside, nucleotide and
nucleic acid metabolism
0.44
WFDC2 ENSG00000101443:MAJOR EPIDIDYMIS-SPECIFIC PROTEIN E4
PRECURSOR
GO:0006508:proteolysis and peptidolysis 0.43
OAS1 † ENSG00000089127:2’,5’-OLIGOADENYLATE SYNTHETASE 1 GO:0006955:immune response 0.42
SERPINH1 ENSG00000149257:COLLAGEN-BINDING PROTEIN 2 PRECURSOR GO:0006950:response to stress 0.39
CYBA ENSG00000051523:CYTOCHROME B-245 ALPHA GO:0006118:electron transport; GO:0006801:
superoxide metabolism
0.38
IFITM2 † ENSG00000185201:INTERFERON-INDUCED TRANSMEMBRANE
PROTEIN 2
GO:0006955:immune response 0.34





ALDH1A1 ENSG00000165092:ALDEHYDE DEHYDROGENASE 1 FAMILY
MEMBER A1
GO:0006081:aldehyde metabolism 0.29
IFITM1 † ENSG00000185885:INTERFERON-INDUCED TRANSMEMBRANE
PROTEIN 1
GO:0006955:immune response; GO:0008285:negative
regulation of cell proliferation
0.25
*G1P2 † ENSG00000182106:UBIQUITIN CROSS-REACTIVE PRECURSOR GO:0006955:immune response; GO:0007267:cell-cell
signaling
0.17
Gene symbol, name, function and fold-change in expression (C3.6 vs. HB4a) at T0 are shown for genes displaying differential expression between cell lines and
which were relatively unresponsive to growth factor. *Indicates that the protein product of this gene displays the same directionality of differential expression
(data from 2D-DIGE and immunoblotting experiments ([38,72,78] and Figure 6)). † Indicates the 8 down-regulated interferon-stimulated genes (ISGs).
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from the microarray. The reason for this discrepancy is
unclear, although the RT-PCR data is likely to provide a
more accurate measure of regulated expression. The
protein expression of several targets was also examined
to test if the observed mRNA changes were indeed
translated at the protein level (Fig. 6 and Additional file
6). When comparing the effect of ErbB2 overexpression
alone (i.e. between cell lines), there was reasonable con-
cordance between relative protein and mRNA expres-
sion for MYC, CLDN4, ZYX, PHB, MAP2K1, NME1,
AGR2, PKM2 and ANXA2, (all up-regulated) and
IGFBP3, ISGF3G and G1P2 (all down-regulated) (Fig.
6B). However, GF-induced changes in protein level were
only apparent for MYC, CLDN4, S100A6, ZYX and
G1P2 (Fig. 6C). In particular, the robust repression of
IGFBP3 mRNA by GF treatment was not observed at
the protein level or the induction of DUSP1 and SFN.
Altered expression of IGFBP3 may alter IGF1-dependent
signalling
Given the reduced expression of IGFBP3 in the C3.6
cells, IGFBP3’s reported role in regulating IGF activity
[35] and the reported aberrant regulation of the IGF sys-
tem in breast cancer [36], we wanted to further examine
if IGF1-induced signalling might be affected by ErbB2
overexpression in these cells. Cells were stimulated with
IGF1 and proliferative and survival signalling assessed
by immunoblotting with antibodies specific to the phos-
phorylated, activated forms of ERK1/2 and Akt. ERK2
phosphorylation was induced more rapidly in the C3.6
cells, though by 10 min the levels were similar in the
two cell lines (Fig. 7A). Akt phosphorylation was also
induced more rapidly, reaching a higher level and was
sustained in the C3.6 cells. These effects were not due
to altered expression of the IGF1 receptor (IGFR),
which was equivalent in the two cell lines (Fig. 7B).
These data show that early IGF1-dependent signalling
events are enhanced in the ErbB2-overexpressing cells
and may contribute to the enhanced proliferation we
observed in the C3.6 cells in response to IGF1 treatment
(Fig. 7C). We next assessed the involvement of ErbB2 in
this phenomenon by targeting ErbB2 knockdown by
transient reverse transfection with specific siRNAs and
examined IGF1 signalling responses by immunoblotting
(Fig. 8). Knockdown of ErbB2 expression in C3.6 cells
(>90%) resulted in a modest reduction of both basal and
IGF1-induced ERK1/2 phosphorylation and substantial
reduction of IGF1-induced Akt phosphorylation (Fig. 8A
and 8B). There was no effect of ErbB2 knockdown or
IGF1 treatment on intracellular IGFBP3 levels. Notably,
partial knockdown of IGFBP3 (~60%) in the HB4a cells
resulted in both enhanced basal ERK1/2 and Akt phos-
phorylation, with little effect on IGF1-stimulated levels
(Fig. 8C). Knockdown of IGFBP3 in C3.6 had little effect
on IGF1-dependent signalling, presumably as its levels
are already very low in these cells (data not shown).
Taken together, these data reveal a positive role for
ErbB2 expression in enhancing IGF1-dependent signal-
ling in these HMLECs, and also suggested that IGFBP3
acts a negative regulator of this signalling.
To further address the functional consequences of a
possible link between ErbB2 and IGFBP3 regulation and
a possible role in breast cancer, cell-based assays were
performed in the ErbB2-overexpressing and invasive
breast cancer cell line SKBR3 after knocking down
ErbB2 and IGFBP3 expression. Knockdown of ErbB2
expression (>95%) resulted in reduced cell invasion
through matrigel (Fig. 9A), reduced proliferation (Fig.
9B) and reduced anchorage-independent colony forma-
tion (Fig. 9C), confirming the dependence of this cell
line on ErbB2 overexpression for its transformed pheno-
type. Conversely, siRNA-mediated knockdown of
IGFBP3 in these cells (~50%), resulted in increased
(~2.3-fold) invasion (Fig. 9A) and increased (~1.75-fold)
anchorage-independent colony formation (Fig. 9C),
whilst proliferation in normal media was not signifi-
cantly altered (Fig. 9B). We conclude that IGFBP3 is an
inhibitor of tumourigenic phenotype and that ErbB2
may promote transformation, at least in part, through
suppression of IGFBP3 expression and promotion of
IGF1-dependent signalling.
Discussion
This study has identified genes whose differential
expression may contribute to ErbB2-dependent transfor-
mation and which define common and specific signal-
ling events induced through EGFR and ErbB3 receptor-
containing complexes. Although we and others have
previously examined ErbB2-dependent gene expression
changes in the same cell model, and find overlap in the
genes identified [37,38], to the best of our knowledge,
this is the first study to simultaneously investigate long-
term ErbB2- and GF-dependent gene expression using
ligands that activate specific ErbB receptor complexes in
the same cell system. A number of gene expression
changes were further validated using qRT-PCR and we
report a good correlation between the datasets, indicat-
ing the robustness of the microarray protocol employed.
There were significantly more HRG-responsive genes
than EGF-responsive genes and in many cases the HRG
response was elevated in the ErbB2-overexpressing cells.
This is likely to be a consequence of the higher expres-
sion of ErbB2 and ErbB3 in these cells [32] and the pre-
ferred heterodimerzation of these receptors [3-6], which
would act to augment the response to HRG. We do not
think that ErbB4 (also a HRGb1 receptor) plays a major
role in orchestrating signalling events in this cell system,
since it appears to be expressed at very low levels, if at
Worthington et al. BMC Cancer 2010, 10:490
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all, in these cell lines (data not shown). Although HRG-
induced expression was generally of a lower magnitude
than for EGF, it was often sustained compared to EGF,
consistent with our previous finding that HRG-depen-
dent mitogenic signalling is sustained in these cells [32].
Such temporal differences may be connected with differ-
ential rates of receptor or signal down-regulation, but
also highlight the fact that the two growth factors initi-
ate diverse responses which are likely to be relevant
in vivo. Genes induced robustly by HRG (ZNF236,
ZFP36L1, ZFP36L2, MADH4, TRIO, HMGCR,
SLC16A1, SLPI, GYS1, SFRS5, CTNND1, LCAT, LYN,
STAT1, KRT15, C20orf16 and FN1) are likely candi-
dates for regulation by the PI3K/Akt pathway which is
Figure 6 Immunoblot validation of differentially expressed genes. A. Relative gene expression for 16 selected genes by microarray or real
time RT-PCR analysis. B. Protein expression for these gene products by immunoblotting. Representative blots from 3-5 independent experiments
are shown, including a beta-actin loading control. Myc protein expression was only examined at the 4 hr timepoint and was not detected at
other time-points. Relative quantification of immunoblotting data is shown in Additional file 6.
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Figure 7 ErbB2-enhances IGF1 signalling and proliferation in
the HMLEC system. A. Cells were starved of serum for 48 hrs and
then stimulated with 25 ng/mL IGF1 for the indicated times.
Activation of ERK1/2 and Akt was assessed by immunoblotting with
phospho-specific antibodies and protein levels checked by re-
probing membranes with non-phospho-specific and beta-actin
antibodies. Blotting data was quantified by densitometry. Intensities
for each band were normalized to the actin band in that lane and
the ratios pAkt/Akt and pERK2/ERK2 calculated. Normalized ratios
were then averaged from 3 independent blots and plotted using
standard deviation as the error. B. Levels of ErbB2, IGFBP3 and IGF1R
in HB4a and C3.6 cells were assessed by immunoblotting. C. MTT
proliferation assays were carried out on HMLECs in media
supplemented with 10% FBS, 0.1% FBS and 0.1% FBS plus 25 ng/mL
IGF1 over a period of 48 hrs.
Figure 8 Effect of siRNA-mediated knockdown of ErbB2
expression on IGF1-stimulated signalling. A. Control siRNA and
siErbB2-transfected C3.6 cells were serum starved for 48 hrs and
then stimulated with 25 ng/mL IGF1 for the indicated times.
Activation of ERK1/2 and Akt was assessed by immunoblotting with
phospho-specific antibodies and protein levels checked by re-
probing membranes with non-phospho-specific, ErbB2, IGFBP3 and
beta-actin antibodies. B. Control siRNA and siErbB2-transfected C3.6
cells were serum starved for 48 hrs and then stimulated with 25 ng/
mL IGF1 for 20 min (+) or left unstimulated (-). Lysates were
immunoblotted as in A. C. Control siRNA and siIGFBP3-transfected
HB4a cells were serum starved for 48 hrs and then stimulated with
25 ng/mL IGF1 for 20 min (+) or left unstimulated (-). Lysates were
immunoblotted as in A.
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Figure 9 Effect of siRNA-mediated knockdown of ErbB2 and IGFBP3 expression on invasiveness, proliferation and anchorage
independent colony formation in SKBR3 cells. A. Control siRNA, siErbB2- and siIGFBP3-transfected SKBR3 cells were subjected to a Matrigel-
based invasion assay as described in the Methods section. The graph shows the number of invaded cells per field for each condition. Images of
stained invaded cells are shown on the right. Knockdowns were confirmed by immunoblotting. B. An MTT-based proliferation assay was carried
out on control siRNA, siErbB2- and siIGFBP3-transfected SKBR3 cells in complete media over 48 hrs. C. Control siRNA, siErbB2- and siIGFBP3-
transfected SKBR3 cells were assayed for anchorage-independent growth using a soft agar colony forming assay (see Methods section). The
graph shows the average number of colonies per field, whilst the images show representative microscopy fields.
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potently activated by HRG through ErbB2-ErbB3 hetero-
dimers [7,8]. Since HRG expression itself correlates with
tumourigenicity and metastasis in breast cancer cells
lines [39,40], it will be interesting to assess whether the
induction of these genes is affected by chemical inhibi-
tion of the PI3K pathway, or whether such inhibitors
would make clinically useful therapeutics for breast can-
cer treatment.
Notably, a group of EGF-specific genes (e.g. AREG,
S100A2 and CTSC) were induced exclusively in the
HB4a cells, potentially through EGFR homodimers
which predominate in these cells [32]. One of these
genes, AREG, is a ligand of EGFR itself, suggesting that
EGF could drive autocrine signalling to enhance EGF-
specific responses. Members of the MT family were also
potently induced by EGF. Whilst induction of MT1
expression by EGF has been shown in rat hepatocytes
[41], this is the first report of MT1 (and MT3) induction
by EGF in human epithelial cells. Since the altered
expression of MT family members has been implicated
in neoplasia and drug resistance [42,43], it will be inter-
esting to investigate whether MT expression is linked to
deregulated GF signalling in cancer.
Many of the identified genes have been previously
implicated in tumour progression, found to be aber-
rantly expressed in different tumour types and/or to be
linked with poor prognosis, hyper-proliferation, cell sur-
vival or tumour invasiveness. Our findings suggest that
dysregulated ErbB signalling can account for changes in
the expression of these genes, and may thus contribute
to the establishment and progression of ErbB2-overex-
pressing breast tumours. For example, of the genes
induced by both GFs and augmented by ErbB2, the
proto-oncogenic transcription factor MYC has been
associated with many forms of cancer often indicating
poor prognosis [44]. Importantly, patient survival was
significantly reduced in breast cancers where MYC and
ErbB2 are co-amplified [45]. The MYC-induced glyco-
protein EMP1 was also similarly regulated and whilst its
function is unknown, it has reported tumourigenic activ-
ity [46] and was identified as a marker of gefinitib-resis-
tance in xenograft models [47]. Thus, one possible
scenario that warrants further investigation is that
EMP1 acts in concert with MYC to promote ErbB2-
dependent proliferation and drug resistance. A pattern
of ErbB2-augmented GF-induction was also observed
for other genes known to be involved in proliferation,
autocrine signalling and anti-apoptosis (e.g. ATF4,
FOSL1, IER3, MAP2K1/MEK1, MAP2K3/MEK3, PDGF,
TNFAIP3, VEGF) and it is possible that these changes
contribute to the reported hyper-proliferative phenotype
of these ErbB2-overexpressing cells [31,32]. Induction of
the pro-angiogenic factor VEGF is particularly relevant
to tumour progression and confirms previous data
[48,49]. Notably, VEGF expression was shown to depend
upon ATF4 expression under certain conditions [50]
and we hypothesize that such a regulatory circuit exists
in these cells, whereby ErbB2-augmented GF signalling
would promote VEGF expression through up-regulation
of ATF4. The induction of some genes was perhaps sur-
prising given their reported functions. GADD45A, SFN
and the dual-specificity phosphatases DUSP1/MKP1 and
DUSP5 were induced by GF treatment and are involved
in genotoxic stress-induced growth arrest [51], p53-
dependent negative regulation of G2/M progression [52]
and down-regulation of MAPK signalling, respectively
[53]. We propose that these may be negative feedback
mechanisms adapted to self-regulate proliferative
signalling.
Conversely, the down-regulation of genes with anti-
proliferative functions identifies mechanisms by which
increased ErbB2 signalling may promote proliferation
and survival. Examples include the multiple ISGs that
were identified and IGFBP3. G1P2/ISG15 was the most
down-regulated gene in the dataset. Like ubiquitin,
G1P2 is conjugated to proteins in a process called ISGy-
lation which appears to modulate protein activity during
the immune response and signalling [54]. The other
ISGs were UBE2L6 (the proposed E2 enzyme for ISGy-
lation [55]), IFIT1, IFITM1, IFITM2, OAS1 and
ISGF3G/p48/IRF9. Notably, ISGF3G is a component of
a transcription factor complex that with STAT1 and
STAT2 controls type I IFN-mediated induction of ISGs
containing interferon-stimulated regulatory elements
(ISREs) [56]. The lowered expression of ISGF3G could
thus account for the down-regulation of the other ISGs
in the ErbB2-overexpressing cells, as suggested by our
previous work [38]. Whilst the ISGs were induced by
IFN treatment in the HMLECs, induction of ISGF3G
(particularly with IFNg) was blocked by GF co-treat-
ment, revealing a possible cross-talk between the IFN
and ErbB signalling pathways (data not shown).
Although preliminary, our data suggested an inverse
correlation between ErbB2 and ISG expression, support-
ing a role for repressed basal ISG expression in the
pathogenesis of ErbB2-dependent breast cancer.
IGFBP3 mRNA and protein expression were both
markedly lower in the ErbB2-overexpressing cells, whilst
mRNA levels were decreased by GF treatment, particu-
larly in the parental cells. Given IGFBP3’s putative role
as a negative regulator of IGF1 signalling [35], its anti-
proliferative role [57] and the negative correlation
between serum IGFBP3 levels and cancer risk [58-60],
we investigated a possible link between its expression
and IGF1 signalling. We found that IGF1-mediated ERK
and Akt activation and proliferation were increased in
the ErbB2-overexpressing cells and that the signalling
effect was reversed by siRNA-mediated knockdown of
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ErbB2. The mechanism by which this occurs is unclear,
although does not involve altered IGF1R expression, and
may be mediated through interaction between ErbB
receptors and IGF1R as previously reported in other cell
models [61-63]. ErbB2 may also down-regulate IGFBP3
expression to promote IGF1 signalling. We propose that
ErbB2-dependent suppression of IGFBP3 expression is a
long-term adaptive response and would be the reason
why IGFBP3 protein levels were not affected by transi-
ent ErbB2 knockdown. We speculate that this may be
due to IGFBP3 promoter methylation, as previously
reported for other cancers [64,65]. In the C3.6 cells,
IGFBP3 expression is suppressed, allowing maximal
IGF1 signalling through ErbB2-IGF1R interaction
[61-63]. Knocking down ErbB2 in these cells therefore
does not affect IGFBP3 levels, but abrogates IFG1 sig-
nalling. In HB4a cells, IGF1 signalling is restricted by
normal IGFBP3 expression with knockdown of IGFBP3
enhancing basal ERK1/2 and Akt activation, thus sup-
porting its role as a negative regulator of proliferation
and survival. Although reduced IGFBP3 expression did
not affect acute IGF1 triggering, our data partly support
findings in primary and immortalized human esophageal
cells, where EGF-mediated down-regulation of IGFBP3
was shown to determine cellular response to IGF1 [66].
However, this effect may be mediated by the as yet
unknown IGF1-independent actions of IGFBP3
(reviewed in [67,68])
The observed increases in invasiveness and anchorage-
independent growth of ErbB2-overexpressing SKBR3
cells following knockdown of IGFBP3 supports a role
for IGFBP3 as a negative regulator of cellular transfor-
mation in breast cancer and we propose that its down-
regulation is a mechanism whereby ErbB2 promotes
tumour cell growth through increased IGF1-dependent
proliferation, survival and invasion. Indeed, a require-
ment for IGF1 in EGF-mediated cell cycle progression
has been shown in primary murine mammary epithelial
cells [69]. Whilst an attractive model, other studies
report that IGFBP3 can potentiate EGF-stimulated pro-
liferation in MCF10A cells [70] and that IGFBP3 expres-
sion is associated with growth stimulation of T47D
human breast cancer cells [71]. These differences may
be explained by cell type-specific effects and are possibly
dependent upon the extent of interaction with the ErbB
receptor system [71]. Future experiments should explore
the effects of overexpressing IGFBP3 on IGF1 signalling,
proliferation, survival and invasion and to investigate the
level of IGFBP3 promoter methylation in this cell
system.
We have previously reported a high correlation
between mRNA and protein expression for a subset of
genes in these cell lines [38], and a previous proteomic
study found reduced expression of GSTP1, PRDX5 and
USP14 and increased expression of KRT13, ALDH1A3
and NME1 in the C3.6 cells [72], in agreement with the
mRNA data presented here. In the present study, the
mRNA expression of several targets (MYC, CLDN4,
S100A6, ZYX, PHB, MAP2K1, NME1, AGR2, PKM2,
IGFBP3, ISGF3G, G1P2 and ANXA2) correlated with
altered protein expression, signifying that these changes
are likely to be functionally relevant. However, correla-
tion between protein and mRNA expression was not
apparent for some targets in response to the GF treat-
ments. For example, the repression of IGFBP3 mRNA
by GF treatment was not confirmed at the protein level
and neither was induction of DUSP1 or SFN. This sug-
gests that the IGFBP3 protein may be relatively stable
over the time course of the assay or that the DUSP1
and SFN mRNAs are not translated. Such post-tran-
scriptional regulatory mechanisms are likely to be
important, and whilst some mRNA changes appear to
be redundant, they may be relevant in other circum-
stances, for example, during development, differentiation
or stress.
A relatively large group of genes involved in regulating
the cytoskeleton, cell adhesion and motility were identi-
fied. Whilst various patterns of gene expression were
apparent, genes up-regulated to a greater degree by
either GF in the ErbB2-overexpressing cells (ZYX, VIM,
VCL, TAGLN, VIL2, PDLIM1, ITGA2, ITGA3, PLAT,
PLAUR, SERPINE1 and ANXA2) are perhaps the most
interesting, since they may promote the ErbB2-mediated
anchorage-independent growth and reduced cellular
adhesion previously observed in this cell model system
[31,38]. Notably, some of these genes are members of
the plasminogen activator system and have been impli-
cated in tumour progression and invasiveness through
proteolysis of the extracellular matrix. Indeed, increased
levels of PLAUR and SERPINE1 have been associated
with poor prognosis in breast cancer patients [73,74].
Our data thus implicates ErbB2-mediated signalling in
the regulation of the plasminogen activator system, as
well as cell adhesion-related events.
Finally, a number of genes of unknown or poorly-
defined function were identified and several were vali-
dated. These include BCAR3, CPNE3, CSRP1, HPCAL1,
LCP1, MGC10471, NME1, SMAP, ZFP36L1, ZFP36L2
and ZNF236, which were differentially regulated by GF
in an ErbB2-dependent manner and AGR2, LOC402057,
NPC2, PSCA, S100P and SERF2, which were differen-
tially expressed in an ErbB2-dependent manner. Our
data reveals that the expression of these genes can be
regulated by ErbB receptor signalling and thus impli-
cates them as possible biomarkers and effectors of
ErbB2-dependent tumourigenesis. Indeed, AGR2, LCP1
and S100P overexpression have been previously corre-
lated with breast cancer progression [75-77], and we
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now link the aberrant expression of these genes with
ErbB2 expression.
Conclusions
Fully understanding and characterising the interactions
and outcomes of the identified gene expression changes
is a huge undertaking and will require additional studies
addressing the functional consequences of such changes.
However our data provides a valuable resource and a
number of testable hypotheses with potentially impor-
tant implications in GF signalling and ErbB2-dependent
tumourigenesis. One assumption of this work is that the
measured effects are indeed ErbB2-dependent and not
an artefact of clonal selection and variation. With this in
mind, future validation work should involve testing of
candidate genes in other clones, mammary cell lines or
breast tumour samples that overexpress ErbB2 and by
RNAi-mediated knockdown of ErbB2 expression to see
if the observed effects can be reversed. Indeed, for one
candidate, IGFBP3, we demonstrate it to be a negative
regulator of transformation using siRNA-dependent
knockdown and propose that its down-regulation
enhances IGF1-dependent signalling in ErbB2-over-
expressing cells.
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Additional file 3: K-means and hierarchical clustering of EGF and
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